ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
Trends in Anti-Müllerian Hormone (AMH) Testing for Fertility Assessment in Australian General Practice, 2011-2021: A Retrospective Open Cohort Study.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAnti-Müllerian hormone (AMH) tests are often promoted as a measure of fertility; however, AMH adds limited predictive value beyond age alone for estimating the likelihood of live birth in couples trying to conceive.
aimsThis study aimed to examine longitudinal trends in the rate of AMH testing for fertility in the Australian general practice setting. MATERIALS AND
methodsRetrospective open cohort study of 1,393,931 females aged 20-44 years attending Australian general practices between 2011 and 2021 using the national general practice database, MedicineInsight. Free text 'test reason' fields were examined to identify AMH tests ordered by General Practitioners for fertility assessment. We calculated age-standardised annual prevalence rates for AMH tests overall, as well as stratified by age group and concession card status. To examine between-practice variation, the intraclass correlation coefficient (ICC) was estimated using a two-level logistic regression model.
resultsThe annual age-standardised prevalence of AMH test requests increased from 0.32 per 1000 females in 2011 to 4.33 per 1000 females in 2021. AMH testing was more common among those residing in a major city and of higher socioeconomic status, but less common among concession card holders. Following adjustment for patient case-mix, 21% (95% CI 18%-24%) of observed variation in AMH testing was attributable to differences between practices, with 45/423 (10.6%) of general practices having no patients with an AMH test.
conclusionsThe noted substantial increase in clinical and consumer demand for AMH testing does not appear to be evidence-based, with substantial patient- and practice-level variation in testing evident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.